High-dose dexamethasone therapy in chronic idiopathic thrombocytopenic purpura.
A high-dose pulse of dexamethasone has been described as a current option for the treatment of refractory idiopathic thrombocytopenic purpura (ITP), but the results are controversial. Here we describe the use of a high does of dexamethasone (40 mg per day for 4 days every month) in 18 patients with chronic ITP. The median age of the patients was 42.5 years (range, 16-77 years); 13 were female and five male. The duration of the disease ranged from 5 to 480 months, and splenectomy was carried out in six of the 18 patients. the overall results obtained revealed a satisfactory response (platelet counts higher than 50 x 10(9)/l) in eight of the 18 patients. However, a long-term remission was achieved in only three of the eight patients with a follow up of 7-16 months. We were not able to identify any clinical or laboratory prognostic parameters or previous treatment which would allow one to predict a successful outcome of this treatment. These results suggest that a high dose of dexamethasone may provide an alternative, be it a poor one, for the treatment of refractory IPT, in which the use of a low-cost drug with limited side effects is an important consideration.
Arruda
V R
VR
Hematology-Hemotherapy Center, State University of Campinas, Brazil.
Annichino-Bizzacchi
J M
JM
D000293:Adolescent; D000328:Adult; D003907:Dexamethasone / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D013156:Splenectomy
D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D003907:Dexamethasone